CRISPR Therapeutics Proposes New Appointment to the Board of Directors
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company's annual general meeting to be held this year.
瑞士楚格和波士顿,2025年1月7日(环球新闻通讯社) -- CRISPR Therapeutics(纳斯达克:CRSP),一家专注于为严重疾病创造变革性基因治疗的生物医药公司,今天宣布拟在公司今年举行的年度股东大会上选举Briggs Morrison万.D.进入董事会。
"We are excited to welcome Briggs to our Board of Directors," said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics. "His extensive experience in the pharmaceutical industry and expertise in clinical development will be a tremendous asset as we continue to advance our innovative platform and pipeline, with the goal of developing transformative medicines for patients suffering from serious diseases."
“我们很高兴欢迎Briggs加入我们的董事会,” CRISPR Therapeutics的首席执行官兼董事会主席Samarth Kulkarni博士说。“他在药品行业的丰富经验和临床开发的专长将是我们继续推进我们的创新平台和产品线的巨大资产,目标是为遭受严重疾病的患者开发变革性药物。”
"I am thrilled to join such an innovative company at the forefront of gene editing," said Briggs Morrison, M.D. "I look forward to collaborating with the Board and the management team to drive CRISPR Therapeutics' vision forward and contribute to its continued success."
“我很高兴能够加入这样一家处于基因编辑前沿的创新公司,”Briggs Morrison万.D.说。“我期待与董事会和管理团队合作,推动CRISPR Therapeutics的愿景向前发展,为其持续成功做出贡献。”
Dr. Morrison currently serves as Chief Executive Officer and as a member of the Board of Directors of Crossbow Therapeutics, Inc. He is trained as a medical oncologist with over 30 years of experience in the pharmaceutical and biotechnology industries, and has held executive roles at Syndax Pharmaceuticals, AstraZeneca PLC, Pfizer Inc., and Merck & Co., Inc. He has overseen the clinical development from Phase 1 through to approval and life cycle management of many approved drugs, including Tagrisso, Imfinzi and Lynparza. Dr. Morrison serves on the Board of Directors of a number of public and private biotechnology companies and is an Entrepreneur Partner at MPM BioImpact. He received his B.S. in Biology from Georgetown University and his M.D. from the University of Connecticut.
Morrison博士目前担任Crossbow Therapeutics, Inc.的首席执行官和董事会成员。他受过医学肿瘤学的训练,拥有超过30年在药品和生物技术行业的经验,并曾在Syndax Pharmaceuticals、阿斯利康、辉瑞和默沙东等公司担任高管。他监督了多个批准药物的临床开发,从第一阶段到批准和生命周期管理,包括Tagrisso、Imfinzi和Lynparza。Morrison博士在多家公共和私营生物技术公司的董事会任职,并且是MPm BioImpact的创业合伙人。他在乔治城大学获得生物学学士学位,并在康涅狄格大学获得医学博士学位。
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company that celebrated the historic approval of the first-ever CRISPR-based therapy in 2023 and has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion-dependent beta thalassemia, and beginning in late 2023, CASGEVY (exagamglogene autotemcel [exa-cel]) was approved in some countries to treat eligible patients with either of those conditions. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. To learn more, visit .
关于CRISPR Therapeutics
自十多年前成立以来,CRISPR Therapeutics已经从一家推进基因编辑领域项目的研发阶段公司,转变为一家在2023年庆祝首个基于CRISPR的疗法历史性批准的公司,并拥有一个涵盖多种疾病领域的多样化产品候选组合,包括血红蛋白病、肿瘤学、再生医学、心血管、自身免疫和罕见疾病。CRISPR Therapeutics在2018年推进了首个CRISPR/Cas9基因编辑疗法进入临床,以调查治疗镰状细胞病或输血依赖型β地中海贫血,并于2023年底开始,CASGEVY(exagamglogene autotemcel [exa-cel])在一些国家获得批准,用于治疗符合条件的患者。获得诺贝尔奖的CRISPR科学已经彻底改变了生物医药研究,代表了一种强大的、临床验证的方法,有潜力创造出新类别的潜在变革性药物。为了加速和扩大其努力,CRISPR Therapeutics已与领先公司建立战略合作伙伴关系,包括拜耳和福泰制药。CRISPR Therapeutics AG总部位于瑞士楚格,拥有全资美国子公司CRISPR Therapeutics, Inc.,以及位于马萨诸塞州波士顿和加利福尼亚州旧金山的研发业务办公室,以及位于英国伦敦的业务办公室。欲了解更多信息,请访问。
CRISPR THERAPEUTICS standard word mark and design logo are registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.
CRISPR THERAPEUTICS 标准商标和设计标识是 CRISPR Therapeutics AG 的注册商标。所有其他商标和注册商标属于其各自的所有者。
CRISPR Special Note Regarding Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, the statements made by Drs. Kulkarni and Morrison in this press release as well as statements regarding any or all of the following: (i) CRISPR Therapeutics' preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials, potential expansion into new indications and expectations regarding data, safety and efficacy generally; (ii) discussions with regulatory authorities related to product candidates under development by CRISPR Therapeutics; and (iii) the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading "Risk Factors" in its most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release other than to the extent required by law.
CRISPR 关于前瞻性声明的特别说明
本新闻稿中关于非历史事实的声明是 1995 年《私人证券诉讼改革法案》意义上的“前瞻性声明”。由于此类声明受到风险和不确定性的影响,实际结果可能与这些前瞻性声明所表达或暗示的内容大相径庭。此类声明包括但不限于 Drs. Kulkarni 和 Morrison 在本新闻稿中所作的声明,以及关于以下任意或所有内容的声明:(i) CRISPR Therapeutics 的前期研究、临床试验及管线产品和项目,包括但不限于,制造能力、此类研究和试验的状态、潜在的新适应症扩展及对数据、安全性和有效性的普遍期望;(ii) 与监管机构就 CRISPR Therapeutics 正在开发的产品候选进行的讨论;(iii) 基因编辑技术和治疗方法(包括 CRISPR/Cas9)的治疗价值、开发和商业潜力。导致前瞻性声明不确定性质的风险包括但不限于,在其最近的 10-k 表格年度报告以及 CRISPR Therapeutics 向美国证券交易委员会提交的任何后续文件中讨论的“风险因素”标题下的风险和不确定性。现有和潜在投资者被警告不要对这些前瞻性声明寄予过高的期望,这些声明仅以其发布之日为准。公司不承担任何义务或责任去更新或修订本新闻稿中包含的任何前瞻性声明,除非法律要求。
Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
投资者联系人:
苏珊·金
+1-617-307-7503
susan.kim@crisprtx.com
Media Contact:
Rachel Eides
+1-617-315-4167
rachel.eides@crisprtx.com
媒体联系人:
瑞秋·艾德斯
+1-617-315-4167
rachel.eides@crisprtx.com
Source: CRISPR Therapeutics AG
来源:CRISPR Therapeutics AG